{"gene":"XRCC1","run_date":"2026-04-28T23:00:23","timeline":{"discoveries":[{"year":1990,"finding":"Molecular cloning of XRCC1 established it as a 633-amino-acid protein (69.5 kDa) required for efficient DNA single-strand break repair; CHO mutant EM9 cells lacking XRCC1 show reduced strand-break rejoining, elevated sister chromatid exchange, and sensitivity to alkylating agents and ionizing radiation.","method":"cDNA cloning, complementation of CHO EM9 mutant, strand-break repair kinetics, cell survival, SCE assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — original gene cloning with functional complementation, multiple orthogonal assays","pmids":["2247054"],"is_preprint":false},{"year":1994,"finding":"XRCC1 physically interacts with DNA ligase III in human cells; XRCC1 is required for normal levels of DNA ligase III activity, implicating this ligase in base excision repair.","method":"Affinity chromatography (His-tagged XRCC1 co-purification), DNA ligase III activity assay in EM9 cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — affinity purification co-purification with functional readout, foundational study >400 citations","pmids":["8264637"],"is_preprint":false},{"year":1996,"finding":"XRCC1 directly interacts with DNA polymerase β (pol β) via residues 84–183 in its N-terminal region; the C-terminal region binds DNA ligase III. XRCC1 suppresses strand displacement by pol β during single-nucleotide BER reconstitution, allowing efficient nick ligation. XRCC1 thus functions as a scaffold protein without catalytic activity.","method":"BER reconstitution with purified recombinant human proteins, far Western blotting, affinity precipitation, yeast two-hybrid, gel retardation (supershift) assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — reconstitution + multiple orthogonal interaction methods, domain mapping, highly cited","pmids":["8978692"],"is_preprint":false},{"year":1997,"finding":"Only the 103 kDa isoform of DNA ligase III (not the testis-specific 96 kDa isoform) interacts with XRCC1; the C-terminal 96 amino acids of XRCC1 are necessary and sufficient for the interaction, and the C-terminal 148 amino acids of DNA ligase III contain the XRCC1-binding site.","method":"Far Western blotting, affinity precipitation of subcloned XRCC1 and DNA ligase III fragments, antipeptide antibodies","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — domain mapping with multiple orthogonal methods, >200 citations","pmids":["9136882"],"is_preprint":false},{"year":1998,"finding":"XRCC1 physically associates with PARP-1 via its central BRCT I domain (amino acids 301–402); XRCC1 overexpression dramatically decreases PARP-1 activity in vivo, identifying XRCC1 as a negative regulator of PARP-1 and placing PARP-1 in a BER multiprotein complex with XRCC1, pol β, and DNA ligase III.","method":"Yeast two-hybrid screen, co-immunoprecipitation in mammalian cells, PARP-1 activity assay after XRCC1 overexpression","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 — yeast two-hybrid + mammalian co-IP + functional assay, >780 citations","pmids":["9584196"],"is_preprint":false},{"year":2001,"finding":"XRCC1 interacts with polynucleotide kinase (PNK) and stimulates PNK's DNA kinase and DNA phosphatase activities at damaged DNA termini; XRCC1, pol β, PNK, and DNA ligase III form multiprotein complexes in human cell extracts that together repair oxidative/ionizing-radiation-type single-strand breaks.","method":"Co-immunoprecipitation, in vitro DNA kinase/phosphatase activity assays, multi-protein SSB repair assay in cell extracts","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — biochemical reconstitution + enzyme activity assay + co-IP, >500 citations","pmids":["11163244"],"is_preprint":false},{"year":2001,"finding":"XRCC1 physically interacts with APE1 and stimulates APE1 endonuclease activity; a truncated APE1 lacking the first 35 amino acids retains catalytic activity but cannot bind XRCC1 and is not stimulated by it. XRCC1-deficient CHO cells have reduced capacity to initiate repair of abasic sites, corrected by XRCC1 expression.","method":"Yeast two-hybrid, co-immunoprecipitation, APE1 activity assay with recombinant proteins, AP-site repair assay in XRCC1-deficient cells","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods including activity assay and cellular complementation, >390 citations","pmids":["11707423"],"is_preprint":false},{"year":2002,"finding":"PARP-2 interacts with XRCC1 (as well as pol β and DNA ligase III); XRCC1 negatively regulates PARP-2 activity similarly to PARP-1. PARP-2-deficient cells show delayed DNA strand-break resealing after alkylation damage, demonstrating a functional role for PARP-2 in BER alongside XRCC1.","method":"Yeast two-hybrid, co-immunoprecipitation, PARP-2 activity assay, PARP-2 knockout mouse cells with strand-break repair kinetics","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — protein interaction, activity assay, and KO cell repair assay; >570 citations","pmids":["11948190"],"is_preprint":false},{"year":2003,"finding":"PARP-1 is required for assembly/stability of XRCC1 nuclear foci at sites of oxidative DNA damage; XRCC1 foci co-localize with poly(ADP-ribose) synthesis and fail to form in PARP-1-null MEFs or when the XRCC1 BRCT I domain is mutated, demonstrating that PARP-1-generated PAR mediates XRCC1 recruitment.","method":"Immunofluorescence microscopy of XRCC1 foci after H2O2, PARP-1 KO MEFs, BRCT I domain point mutants of XRCC1","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — live-cell imaging + genetic KO + domain mutants, >540 citations","pmids":["14500814"],"is_preprint":false},{"year":2004,"finding":"XRCC1 co-localizes with PCNA at DNA replication foci in S phase and physically interacts with PCNA in vivo; in vitro the interaction is mediated by XRCC1 residues 166–310. This suggests XRCC1 is recruited to replication factories via PCNA to facilitate SSBR during S phase.","method":"Immunofluorescence co-localization, FRET analysis, co-immunoprecipitation, in vitro binding with XRCC1 fragments","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (FRET, co-IP, in vitro mapping), >160 citations","pmids":["15107487"],"is_preprint":false},{"year":2004,"finding":"PARP-1 and the XRCC1–DNA ligase III complex participate in an alternative, DNA-PK-independent pathway for DNA double-strand break end-joining; PARP-1 provides synapsis activity and XRCC1–ligase III provides ligation in this alt-EJ route.","method":"In vitro synapsis and end-joining two-step assay with nuclear extracts and recombinant proteins, PARP inhibitor cytotoxicity, DSB repair kinetics","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — biochemical reconstitution with purified proteins, >550 citations","pmids":["15498778"],"is_preprint":false},{"year":2005,"finding":"The primary biochemical defect in XRCC1-deficient cells is impaired nick ligation (~2–4-fold reduction); base excision (8-oxoG, 5-HC, εA, uracil), AP-site incision, and pol β gap-filling activities are normal in XRCC1-deficient extracts, demonstrating XRCC1's key role is at the ligation step of BER/SSBR.","method":"Whole-cell extract BER and SSBR assays, 8-oxoG and AP-site measurement by HPLC/GC-MS in EM9 cells","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic in vitro biochemical dissection of BER steps in XRCC1-deficient extracts","pmids":["16245950"],"is_preprint":false},{"year":2010,"finding":"Casein kinase 2 (CK2) is the major kinase phosphorylating XRCC1 in human cell extracts; CK2-mediated phosphorylation stabilizes the XRCC1–DNA ligase IIIα complex, and mutation of CK2 phosphorylation sites or CK2 siRNA knockdown destabilizes the complex, reduces ligase III levels, and causes accumulation of DNA strand breaks.","method":"Unbiased kinase activity assay in cell extracts, CK2 siRNA knockdown, CK2-site mutants of XRCC1, co-immunoprecipitation, comet assay","journal":"DNA repair","confidence":"High","confidence_rationale":"Tier 1–2 — kinase identification by biochemical assay + site mutagenesis + genetic knockdown with functional readout","pmids":["20471329"],"is_preprint":false},{"year":2011,"finding":"Conditional neural knockout studies reveal that DNA ligase 1 (not ligase III) is the main ligase for XRCC1-mediated nuclear DNA repair; LIG3's essential function is in mitochondrial DNA maintenance, dissociating the cellular roles of XRCC1 and LIG3.","method":"Tissue-specific (neural) conditional knockout mice for XRCC1 and LIG3, phenotypic comparison, mitochondrial DNA maintenance assays","journal":"Cell cycle (Georgetown, Tex.)","confidence":"High","confidence_rationale":"Tier 2 — genetic dissection with mouse KO models revealing distinct in vivo roles","pmids":["21636980"],"is_preprint":false},{"year":2015,"finding":"The phosphate-binding pocket of the XRCC1 BRCT1 domain selectively binds poly(ADP-ribose) at low PAR levels and is required for interaction with cellular PARP-1, XRCC1 accumulation at UVA/H2O2 damage sites and PCNA foci, and XRCC1-dependent acceleration of SSBR, BER, and cell survival after DNA damage.","method":"PAR-binding assays with BRCT1 mutants, co-immunoprecipitation with PARP-1, EGFP-XRCC1 live-cell damage-recruitment assays, BER/SSBR reporter assays, clonogenic survival","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 — domain mutagenesis + binding assay + cellular recruitment + functional repair assays, multiple orthogonal methods","pmids":["26130715"],"is_preprint":false},{"year":2016,"finding":"Biallelic loss-of-function mutations in human XRCC1 cause ocular motor apraxia, axonal neuropathy, and progressive cerebellar ataxia, associated with reduced SSBR and elevated protein ADP-ribosylation (PARP hyperactivation). Genetic deletion of Parp1 in Xrcc1-deficient mice rescues cerebellar ADP-ribose levels, reduces cerebellar neuron loss, and alleviates ataxia, identifying PARP1 hyperactivation as the pathogenic mechanism.","method":"Patient cell studies (SSBR rates, PAR levels), Xrcc1/Parp1 double-KO mouse model, cerebellar neuron counting, ADP-ribosylation quantification","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — human genetics + mouse double-KO genetic rescue with defined molecular and cellular phenotypes, >200 citations","pmids":["28002403"],"is_preprint":false},{"year":2016,"finding":"XRCC1 is an indispensable mediator of muscle differentiation: caspase-triggered DNA strand breaks during myoblast differentiation are rapidly followed by XRCC1 repair foci formation in myonuclei, and skeletal-myoblast-specific deletion of Xrcc1 does not affect cell growth but causes perinatal lethality with sustained DNA damage and impaired myofiber development.","method":"Conditional Xrcc1 knockout in skeletal myoblasts, immunofluorescence of XRCC1 repair foci, γH2AX staining, myofiber morphology analysis","journal":"Cell discovery","confidence":"High","confidence_rationale":"Tier 2 — tissue-specific KO with defined phenotype linked to XRCC1 repair foci dynamics","pmids":["27462438"],"is_preprint":false},{"year":2017,"finding":"Either PARP1 or PARP2 alone is sufficient for near-normal XRCC1 recruitment to oxidative single-strand breaks; loss of both PARP1 and PARP2 together is required to greatly reduce or ablate XRCC1 chromatin binding after H2O2. Very low levels of ADP-ribosylation (by either enzyme) are sufficient for XRCC1 recruitment. PNKP recruitment similarly requires PARP1/2 redundancy.","method":"Isogenic PARP1/PARP2/PARP3 single and double KO human diploid cells, H2O2-induced XRCC1 and PNKP chromatin fractionation, PARP inhibitor dose-response","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — isogenic genetic knockouts with quantitative chromatin binding assay, multiple combinations","pmids":["27965414"],"is_preprint":false},{"year":2018,"finding":"KDM5B demethylates H3K4 at DNA damage sites and facilitates XRCC1 recruitment; increased KDM5B in cisplatin-resistant gastric cancer cells promotes H3K4 demethylation, enabling XRCC1 co-localization with γH2AX. HSP90 stabilizes KDM5B via direct complex formation. KDM5B or HSP90 inhibition blocks XRCC1 recruitment to damage, restoring drug sensitivity.","method":"Co-immunoprecipitation, γH2AX/XRCC1 co-localization imaging, KDM5B knockdown/overexpression, JIB-04 inhibitor, HSP90 inhibitor 17-AAG, mass spectrometry","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2–3 — co-IP + imaging + inhibitor studies in a single lab; chromatin-level mechanism proposed","pmids":["29989047"],"is_preprint":false},{"year":2018,"finding":"PNKP interacts with XRCC1 through two distinct interfaces: the PNKP FHA domain binds phosphorylated XRCC1 (extending beyond residues 515–526), and an XRCC1 fragment (residues 166–436) binds the PNKP catalytic domain and tightly activates PNKP kinase activity. XRCC1 SNP variants R194W and R280H show substantially weaker PNKP binding and severely reduced PNKP stimulation, and cells expressing these variants show reduced PNKP recruitment to laser-induced DNA damage.","method":"In vitro binding and PNKP kinase activity assays with recombinant XRCC1 fragments and SNP variants, laser microirradiation/live-cell recruitment imaging","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — enzyme activity assay + domain mapping + cell-based recruitment with disease-relevant SNP variants","pmids":["30446622"],"is_preprint":false},{"year":2019,"finding":"SIRT1 deacetylates XRCC1 at lysines K260, K298, and K431, preventing β-TrCP-mediated ubiquitination and proteasomal degradation of XRCC1. Mutations at these three sites abrogate β-TrCP interaction and prolong XRCC1 half-life; SIRT1 knockdown reduces XRCC1 stability and enhances DNA damage, contributing to chemoresistance.","method":"Co-immunoprecipitation, ubiquitination assay, site-directed mutagenesis, cycloheximide chase (half-life), SIRT1 KD by siRNA/inhibitor","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1–2 — PTM identification by site mutagenesis + stability assay + E3 ligase identification","pmids":["31043584"],"is_preprint":false},{"year":2019,"finding":"XRCC1 contains a central DNA-binding domain (CDB, residues 219–415) encompassing the BRCT1 domain that lacks specificity for nicked/gapped DNA. Alanine substitution of CDB residues abolishes DNA binding in vitro and significantly reduces XRCC1 retention (but not initial recruitment) at DNA damage sites, and reduced retention is associated with an increased rate of repair, suggesting DNA binding regulates dwell time at damage.","method":"Electrophoretic mobility shift assay, alanine scanning mutagenesis, live-cell XRCC1-GFP retention assay at laser-induced damage sites","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1–2 — domain mapping by mutagenesis + in vitro DNA binding + live-cell functional imaging","pmids":["30816207"],"is_preprint":false},{"year":2020,"finding":"After replication stress, XRCC1 forms an active repair complex with POLQ and MRE11 that supports alternative end-joining (alt-EJ) in vitro; BRCA2 normally limits XRCC1 recruitment to suppress alt-EJ at stalled forks. Without BRCA2 fork protection, XRCC1 enables replication completion via MRE11-dependent fork resection and restart, at the cost of increased genome instability.","method":"In vitro alt-EJ reconstitution with XRCC1/POLQ/MRE11, BRCA2-XRCC1 co-depletion, fork restart/resection assays, chromosome aberration analysis","journal":"NAR cancer","confidence":"Medium","confidence_rationale":"Tier 1–2 — in vitro reconstitution + genetic epistasis in BRCA2-deficient cells; single lab","pmids":["32776008"],"is_preprint":false},{"year":2021,"finding":"XRCC1 prevents 'toxic PARP1 trapping' during BER: protein complexes of pol β and DNA ligase III assembled by XRCC1 prevent excessive PARP1 engagement at BER intermediates. In XRCC1-deficient cells (and patient fibroblasts), PARP1 becomes trapped on BER intermediates—similar to PARP-inhibitor trapping—blocking pol β access and impeding repair. PARP1 deletion rescues BER and resistance to base damage in XRCC1−/− cells.","method":"Trapping assay (PARP1 chromatin fractionation), BER intermediate accumulation assay, PARP1-XRCC1 double KO cells, patient-derived fibroblasts, base damage sensitivity (clonogenic)","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 — mechanistic trapping assay + genetic double KO rescue + patient cells + multiple orthogonal assays","pmids":["34102106"],"is_preprint":false},{"year":2021,"finding":"XRCC1-deficient human cells and patient fibroblasts fail to recover transcription after DNA base damage due to excessive/aberrant PARP1 activity during BER. This aberrant PARP1 activity promotes excessive recruitment of ubiquitin protease USP3, which reduces monoubiquitinated histones required for normal transcription. Inhibition or deletion of PARP1 or USP3 restores transcriptional recovery in XRCC1−/− cells.","method":"Transcription recovery assay (EU incorporation) in XRCC1 KO cells, patient fibroblasts, Xrcc1−/− neurons; PARP1 and USP3 KO/inhibition rescue experiments; ubiquitin-histone western blotting","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — genetic KOs + patient cells + mouse neurons + specific pathway placement via USP3/histone ubiquitination mechanism","pmids":["34811483"],"is_preprint":false},{"year":2022,"finding":"XRCC1 and PARP1 exhibit a reciprocal relationship at DNA damage sites: recruitment of each protein is impeded in the absence of the other. XRCC1 KO cells show hypersensitivity (excess NAD+ depletion, cytotoxicity) to topoisomerase I inhibitor camptothecin compared to PARP1 KO cells, and additional PARP1 deletion or pharmacological PARP inhibition rescues this hypersensitivity and partially restores DNA repair in XRCC1 KO cells.","method":"PARP1 KO, XRCC1 KO, and PARP1/XRCC1 double KO HeLa cells; PARylation assay, NAD+ quantification, clonogenic survival, cell-cycle analysis, comet assay","journal":"Cell biology and toxicology","confidence":"High","confidence_rationale":"Tier 2 — isogenic genetic KO panel with multiple cellular endpoints demonstrating reciprocal regulation","pmids":["35778544"],"is_preprint":false}],"current_model":"XRCC1 is a scaffolding protein without intrinsic catalytic activity that coordinates DNA single-strand break repair (SSBR) and base excision repair (BER) by assembling multi-enzyme complexes: its N-terminal domain binds DNA polymerase β (residues 84–183), its central BRCT1 domain binds poly(ADP-ribose) (PAR) synthesized by PARP1/PARP2 to enable damage-site recruitment, and its C-terminal region binds DNA ligase IIIα; it also stimulates PNK and APE1 activities, is stabilized by CK2-mediated phosphorylation and SIRT1-mediated deacetylation (preventing β-TrCP ubiquitination), and critically functions as an 'anti-trapper' that prevents toxic PARP1 engagement on BER intermediates—loss of XRCC1 leads to PARP1 hyperactivation, transcriptional suppression via USP3-mediated histone de-ubiquitination, and neurodegeneration rescued by PARP1 deletion."},"narrative":{"teleology":[{"year":1990,"claim":"Cloning XRCC1 established it as a gene essential for single-strand break repair, resolving the molecular identity behind the radiation-sensitive CHO EM9 complementation group and linking it to alkylating-agent sensitivity and elevated sister chromatid exchange.","evidence":"cDNA cloning and functional complementation of CHO EM9 cells with strand-break repair kinetics, SCE, and survival assays","pmids":["2247054"],"confidence":"High","gaps":["No catalytic activity or interaction partners identified","Mechanism of XRCC1 action in repair unknown"]},{"year":1996,"claim":"Identification of DNA ligase III and DNA polymerase β as direct XRCC1 partners, with domain mapping, established that XRCC1 is a non-catalytic scaffold that coordinates the ligation and gap-filling steps of BER.","evidence":"BER reconstitution with purified proteins, far Western blotting, yeast two-hybrid, and affinity precipitation with domain fragments","pmids":["8264637","8978692","9136882"],"confidence":"High","gaps":["No information on how XRCC1 is recruited to damage sites","Role of other potential partners unexplored"]},{"year":1998,"claim":"Discovery that XRCC1 physically associates with PARP-1 via its BRCT1 domain and negatively regulates PARP-1 activity revealed a regulatory link between damage sensing and scaffold-mediated repair assembly.","evidence":"Yeast two-hybrid, co-immunoprecipitation, and PARP-1 activity assay after XRCC1 overexpression","pmids":["9584196"],"confidence":"High","gaps":["Whether PARP-1 activity is required for XRCC1 recruitment not yet tested","PARP-2 relationship unknown"]},{"year":2001,"claim":"Expansion of the XRCC1 interactome to include PNK and APE1, with demonstration that XRCC1 stimulates their enzymatic activities, established XRCC1 as a hub that accelerates multiple enzymatic steps in SSBR beyond ligation.","evidence":"Co-immunoprecipitation, in vitro kinase/phosphatase and endonuclease activity assays, cellular complementation of XRCC1-deficient cells","pmids":["11163244","11707423"],"confidence":"High","gaps":["Structural basis for enzymatic stimulation unknown","Relative contributions of each interaction to overall repair rate not quantified"]},{"year":2003,"claim":"Demonstration that PARP-1-generated poly(ADP-ribose) is required for XRCC1 nuclear focus formation answered how XRCC1 is recruited to damage sites, placing PAR as the upstream signal.","evidence":"Immunofluorescence of XRCC1 foci in PARP-1 KO MEFs and BRCT1 mutants after H₂O₂","pmids":["14500814"],"confidence":"High","gaps":["PARP-2 redundancy not tested","Whether PAR binding is direct via BRCT1 or indirect not resolved"]},{"year":2005,"claim":"Systematic biochemical dissection showed the primary defect in XRCC1-deficient cells is impaired nick ligation rather than base excision or gap filling, pinpointing the rate-limiting step controlled by XRCC1.","evidence":"Whole-cell extract BER/SSBR assays across multiple substrates in EM9 cells","pmids":["16245950"],"confidence":"High","gaps":["Whether this reflects ligase III stabilization or direct ligation stimulation not distinguished"]},{"year":2010,"claim":"Identification of CK2 as the kinase that phosphorylates XRCC1 to stabilize the XRCC1–ligase IIIα complex provided the first post-translational regulatory mechanism controlling XRCC1 protein levels and repair capacity.","evidence":"Kinase activity screen in cell extracts, CK2 siRNA, phosphosite mutants, co-immunoprecipitation, comet assay","pmids":["20471329"],"confidence":"High","gaps":["Other kinases or phosphatases that modulate XRCC1 not explored","CK2 regulation in response to damage not characterized"]},{"year":2015,"claim":"Direct PAR binding by the XRCC1 BRCT1 phosphate-binding pocket was shown to be necessary for PARP-1 interaction, damage recruitment, and repair acceleration, resolving that XRCC1 senses PAR through its BRCT1 domain rather than through protein–protein contact with PARP-1.","evidence":"PAR-binding assays with BRCT1 mutants, PARP-1 co-IP, live-cell damage recruitment, BER/SSBR and clonogenic assays","pmids":["26130715"],"confidence":"High","gaps":["Structural details of BRCT1–PAR interaction at atomic resolution not available"]},{"year":2016,"claim":"Human XRCC1 biallelic loss-of-function mutations were linked to cerebellar ataxia and neurodegeneration, and genetic rescue by PARP1 deletion in mice identified PARP1 hyperactivation as the pathogenic driver, transforming understanding from a DNA repair deficiency model to one of toxic PARP1 signaling.","evidence":"Patient fibroblast SSBR/PAR assays, Xrcc1/Parp1 double-KO mouse with cerebellar neuron counts and ADP-ribosylation quantification","pmids":["28002403"],"confidence":"High","gaps":["Downstream effectors of toxic PARylation in neurons not fully delineated","Whether other tissues are similarly affected by PARP hyperactivation unknown"]},{"year":2017,"claim":"Establishing that PARP1 and PARP2 are redundant for XRCC1 recruitment explained why single PARP KOs show mild repair phenotypes, requiring loss of both PARPs to ablate XRCC1 chromatin binding.","evidence":"Isogenic PARP1/PARP2 single and double KO human cells with chromatin fractionation after H₂O₂","pmids":["27965414"],"confidence":"High","gaps":["Whether PARP3 contributes under specific damage contexts not fully excluded"]},{"year":2019,"claim":"Discovery that SIRT1-mediated deacetylation protects XRCC1 from β-TrCP-dependent ubiquitination and degradation identified a second post-translational axis (acetylation/ubiquitination) controlling XRCC1 stability, complementing the CK2 phosphorylation mechanism.","evidence":"Site-directed mutagenesis of K260/K298/K431, ubiquitination assay, cycloheximide chase, SIRT1 knockdown","pmids":["31043584"],"confidence":"High","gaps":["Acetyltransferase that targets these lysines not identified","Interplay between CK2 phosphorylation and SIRT1 deacetylation not studied"]},{"year":2021,"claim":"The 'anti-trapper' model was established: XRCC1 prevents toxic PARP1 trapping on BER intermediates, and in its absence PARP1 hyperactivation triggers USP3-mediated histone de-ubiquitination that suppresses transcription — unifying the repair scaffold and transcription-recovery phenotypes under one mechanism.","evidence":"PARP1 chromatin trapping assay, BER intermediate accumulation, PARP1/XRCC1 double KO rescue, EU-incorporation transcription recovery, USP3 KO/inhibition in patient fibroblasts and mouse neurons","pmids":["34102106","34811483"],"confidence":"High","gaps":["Whether PARP1 trapping contributes to alt-EJ phenotypes not tested","Structural basis for how XRCC1 displaces trapped PARP1 unknown"]},{"year":null,"claim":"Key unresolved questions include the atomic-resolution structural basis for how XRCC1 displaces trapped PARP1 from BER intermediates, the complete spectrum of post-translational modifications governing XRCC1 regulation in vivo, and the extent to which XRCC1's role in alternative end-joining at replication forks contributes to genome instability in BRCA-deficient cancers.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of full-length XRCC1 in complex with trapped PARP1","Complete PTM regulatory network not mapped","Alt-EJ role at replication forks studied in single lab only"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,5,6,11,23]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[21]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,8,9,14,16]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[8,14,17]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[0,2,5,6,11,14,15,23,25]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[15]}],"complexes":["XRCC1–DNA ligase IIIα complex","XRCC1–pol β–ligase III–PARP1 BER complex","XRCC1–PNK–pol β–ligase III SSBR complex"],"partners":["LIG3","POLB","PARP1","PARP2","PNKP","APEX1","PCNA","CSNK2A1"],"other_free_text":[]},"mechanistic_narrative":"XRCC1 is a scaffold protein that coordinates DNA single-strand break repair (SSBR) and base excision repair (BER) by assembling multi-enzyme repair complexes at sites of DNA damage. Its N-terminal domain binds DNA polymerase β (residues 84–183), its central BRCT1 domain binds poly(ADP-ribose) synthesized by PARP1/PARP2 to mediate damage-site recruitment, and its C-terminal region binds DNA ligase IIIα; it also stimulates the enzymatic activities of polynucleotide kinase and APE1, with its protein stability regulated by CK2 phosphorylation and SIRT1-mediated deacetylation that prevents β-TrCP ubiquitination [PMID:8978692, PMID:26130715, PMID:11163244, PMID:11707423, PMID:20471329, PMID:31043584]. A critical function of XRCC1 is to act as an anti-trapper that prevents toxic PARP1 engagement on BER intermediates; loss of XRCC1 causes PARP1 hyperactivation leading to transcriptional suppression via USP3-mediated histone de-ubiquitination, NAD+ depletion, and neurodegeneration that is rescued by PARP1 deletion [PMID:34102106, PMID:34811483, PMID:35778544]. Biallelic loss-of-function mutations in human XRCC1 cause ocular motor apraxia, axonal neuropathy, and progressive cerebellar ataxia driven by PARP1 hyperactivation [PMID:28002403]."},"prefetch_data":{"uniprot":{"accession":"P18887","full_name":"DNA repair protein XRCC1","aliases":["X-ray repair cross-complementing protein 1"],"length_aa":633,"mass_kda":69.5,"function":"Scaffold protein involved in DNA single-strand break repair by mediating the assembly of DNA break repair protein complexes (PubMed:11163244, PubMed:28002403). Negatively regulates ADP-ribosyltransferase activity of PARP1 during base-excision repair in order to prevent excessive PARP1 activity (PubMed:28002403, PubMed:34102106, PubMed:34811483). Recognizes and binds poly-ADP-ribose chains: specifically binds auto-poly-ADP-ribosylated PARP1, limiting its activity (PubMed:14500814, PubMed:34102106, PubMed:34811483)","subcellular_location":"Nucleus; Chromosome","url":"https://www.uniprot.org/uniprotkb/P18887/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/XRCC1","classification":"Not Classified","n_dependent_lines":301,"n_total_lines":1208,"dependency_fraction":0.24917218543046357},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"HMGN5","stoichiometry":0.2},{"gene":"NUMA1","stoichiometry":0.2},{"gene":"PARP1","stoichiometry":0.2},{"gene":"PBK","stoichiometry":0.2},{"gene":"SSRP1","stoichiometry":0.2},{"gene":"TDP1","stoichiometry":0.2},{"gene":"TOP1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/XRCC1","total_profiled":1310},"omim":[{"mim_id":"617633","title":"SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 26; SCAR26","url":"https://www.omim.org/entry/617633"},{"mim_id":"615884","title":"ADIPOCYTE PLASMA MEMBRANE-ASSOCIATED PROTEIN; APMAP","url":"https://www.omim.org/entry/615884"},{"mim_id":"611035","title":"APRATAXIN- AND PNKP-LIKE FACTOR; APLF","url":"https://www.omim.org/entry/611035"},{"mim_id":"607725","title":"POLY(ADP-RIBOSE) POLYMERASE 2; PARP2","url":"https://www.omim.org/entry/607725"},{"mim_id":"607207","title":"STIP1 HOMOLOGOUS AND U BOX-CONTAINING PROTEIN 1; STUB1","url":"https://www.omim.org/entry/607207"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/XRCC1"},"hgnc":{"alias_symbol":[],"prev_symbol":["RCC"]},"alphafold":{"accession":"P18887","domains":[{"cath_id":"2.60.120.260","chopping":"4-155","consensus_level":"high","plddt":90.7143,"start":4,"end":155},{"cath_id":"3.40.50.10190","chopping":"315-402","consensus_level":"high","plddt":90.4057,"start":315,"end":402},{"cath_id":"3.40.50.10190","chopping":"548-628","consensus_level":"high","plddt":92.5044,"start":548,"end":628}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P18887","model_url":"https://alphafold.ebi.ac.uk/files/AF-P18887-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P18887-F1-predicted_aligned_error_v6.png","plddt_mean":69.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=XRCC1","jax_strain_url":"https://www.jax.org/strain/search?query=XRCC1"},"sequence":{"accession":"P18887","fasta_url":"https://rest.uniprot.org/uniprotkb/P18887.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P18887/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P18887"}},"corpus_meta":[{"pmid":"9136882","id":"PMC_9136882","title":"XRCC1 protein interacts with one of two distinct forms of DNA ligase III.","date":"1997","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9136882","citation_count":226,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28002403","id":"PMC_28002403","title":"XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia.","date":"2016","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28002403","citation_count":219,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21952069","id":"PMC_21952069","title":"Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.","date":"2011","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/21952069","citation_count":212,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31856918","id":"PMC_31856918","title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).","date":"2019","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31856918","citation_count":199,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20679884","id":"PMC_20679884","title":"Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.","date":"2010","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20679884","citation_count":173,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27965414","id":"PMC_27965414","title":"Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27965414","citation_count":163,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15107487","id":"PMC_15107487","title":"XRCC1 co-localizes and physically interacts with PCNA.","date":"2004","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/15107487","citation_count":162,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12565173","id":"PMC_12565173","title":"Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer.","date":"2003","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/12565173","citation_count":158,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34102106","id":"PMC_34102106","title":"XRCC1 prevents toxic PARP1 trapping during DNA base excision repair.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/34102106","citation_count":155,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28644440","id":"PMC_28644440","title":"LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals.","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/28644440","citation_count":136,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31324530","id":"PMC_31324530","title":"XRCC1 protein; Form and function.","date":"2019","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/31324530","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10743659","id":"PMC_10743659","title":"Molecular cloning, functional expression and characterisation of RCC reductase involved in chlorophyll catabolism.","date":"2000","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10743659","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25795425","id":"PMC_25795425","title":"The structural basis of XRCC1-mediated DNA repair.","date":"2015","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/25795425","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11867203","id":"PMC_11867203","title":"XRCC1 polymorphisms and head and neck cancer.","date":"2002","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/11867203","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26130715","id":"PMC_26130715","title":"The XRCC1 phosphate-binding pocket binds poly (ADP-ribose) and is required for XRCC1 function.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/26130715","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12359351","id":"PMC_12359351","title":"Genetic polymorphisms of XRCC1 and risk of gastric cancer.","date":"2002","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/12359351","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16621887","id":"PMC_16621887","title":"Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma.","date":"2006","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/16621887","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17116943","id":"PMC_17116943","title":"Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer.","date":"2006","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17116943","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16550161","id":"PMC_16550161","title":"Mouse models of XRCC1 DNA repair polymorphisms and cancer.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16550161","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20218899","id":"PMC_20218899","title":"Genetic variants of XRCC1, APE1, and ADPRT genes and risk of bladder cancer.","date":"2010","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20218899","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34811483","id":"PMC_34811483","title":"XRCC1 protects transcription from toxic PARP1 activity during DNA base excision repair.","date":"2021","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/34811483","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29989047","id":"PMC_29989047","title":"KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance.","date":"2018","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29989047","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23225521","id":"PMC_23225521","title":"Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23225521","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24053727","id":"PMC_24053727","title":"Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC).","date":"2014","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/24053727","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30617728","id":"PMC_30617728","title":"A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).","date":"2019","source":"Molecular imaging and biology","url":"https://pubmed.ncbi.nlm.nih.gov/30617728","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15533591","id":"PMC_15533591","title":"Polymorphisms of XRCC1 and risk of esophageal and gastric cardia cancer.","date":"2004","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15533591","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36445063","id":"PMC_36445063","title":"STING Suppresses Mitochondrial VDAC2 to Govern RCC Growth Independent of Innate Immunity.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36445063","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31043584","id":"PMC_31043584","title":"SIRT1 deacetylated and stabilized XRCC1 to promote chemoresistance in lung cancer.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31043584","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15800946","id":"PMC_15800946","title":"Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15800946","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21604176","id":"PMC_21604176","title":"Polymorphisms of XRCC1 and gastric cancer susceptibility: a meta-analysis.","date":"2011","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21604176","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17264068","id":"PMC_17264068","title":"XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk.","date":"2007","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17264068","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20471329","id":"PMC_20471329","title":"XRCC1 phosphorylation by CK2 is required for its stability and efficient DNA repair.","date":"2010","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/20471329","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26526752","id":"PMC_26526752","title":"A river model to map convergent cancer evolution and guide therapy in RCC.","date":"2015","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/26526752","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32776008","id":"PMC_32776008","title":"XRCC1 promotes replication restart, nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cells.","date":"2020","source":"NAR cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32776008","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33510354","id":"PMC_33510354","title":"Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33510354","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30534127","id":"PMC_30534127","title":"Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30534127","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33087283","id":"PMC_33087283","title":"XRCC1 - Strategies for coordinating and assembling a versatile DNA damage response.","date":"2020","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/33087283","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22249190","id":"PMC_22249190","title":"Epigenetic regulation in RCC: opportunities for therapeutic intervention?","date":"2012","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/22249190","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14639127","id":"PMC_14639127","title":"CYP1A1 and XRCC1 gene polymorphisms in SCC of the larynx.","date":"2003","source":"European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)","url":"https://pubmed.ncbi.nlm.nih.gov/14639127","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24471825","id":"PMC_24471825","title":"The impact of perioperative blood transfusion on survival after nephrectomy for non-metastatic renal cell carcinoma (RCC).","date":"2014","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/24471825","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17935911","id":"PMC_17935911","title":"Menopausal age and XRCC1 gene polymorphisms: role in breast cancer risk.","date":"2007","source":"Cancer detection and prevention","url":"https://pubmed.ncbi.nlm.nih.gov/17935911","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22025172","id":"PMC_22025172","title":"The complex roles of Wnt antagonists in RCC.","date":"2011","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/22025172","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19673050","id":"PMC_19673050","title":"Polymorphisms of XRCC1 gene and risk of gastric cardiac adenocarcinoma.","date":"2009","source":"Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus","url":"https://pubmed.ncbi.nlm.nih.gov/19673050","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26304926","id":"PMC_26304926","title":"Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26304926","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19528960","id":"PMC_19528960","title":"Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.","date":"2009","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/19528960","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26231735","id":"PMC_26231735","title":"Infiltrating neutrophils promote renal cell carcinoma (RCC) proliferation via modulating androgen receptor (AR) → c-Myc signals.","date":"2015","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26231735","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33658305","id":"PMC_33658305","title":"Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33658305","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31201813","id":"PMC_31201813","title":"SIRT1 downregulated FGB expression to inhibit RCC tumorigenesis by destabilizing STAT3.","date":"2019","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/31201813","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26876207","id":"PMC_26876207","title":"Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26876207","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31602010","id":"PMC_31602010","title":"Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities.","date":"2019","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/31602010","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33949971","id":"PMC_33949971","title":"Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC.","date":"2021","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33949971","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26815503","id":"PMC_26815503","title":"SUSD2 is frequently downregulated and functions as a tumor suppressor in RCC and lung cancer.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26815503","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16245950","id":"PMC_16245950","title":"DNA damage levels and biochemical repair capacities associated with XRCC1 deficiency.","date":"2005","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16245950","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31669203","id":"PMC_31669203","title":"PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/31669203","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25799553","id":"PMC_25799553","title":"A comparison of radiologic tumor volume and pathologic tumor volume in renal cell carcinoma (RCC).","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25799553","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32805488","id":"PMC_32805488","title":"MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC.","date":"2020","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/32805488","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26938431","id":"PMC_26938431","title":"Association Studies Between XRCC1, XRCC2, XRCC3 Polymorphisms and Differentiated Thyroid Carcinoma.","date":"2016","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26938431","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33535553","id":"PMC_33535553","title":"Identification of RCC Subtype-Specific microRNAs-Meta-Analysis of High-Throughput RCC Tumor microRNA Expression Data.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33535553","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37173306","id":"PMC_37173306","title":"PRMT2 promotes RCC tumorigenesis and metastasis via enhancing WNT5A transcriptional expression.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37173306","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27793664","id":"PMC_27793664","title":"Rock2 promotes RCC proliferation by decreasing SCARA5 expression through β-catenin/TCF4 signaling.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27793664","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27462438","id":"PMC_27462438","title":"Temporal activation of XRCC1-mediated DNA repair is essential for muscle differentiation.","date":"2016","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/27462438","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22843073","id":"PMC_22843073","title":"MLH1 and XRCC1 polymorphisms in Mexican patients with colorectal cancer.","date":"2012","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/22843073","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31579262","id":"PMC_31579262","title":"The Impact Of Succinate Dehydrogenase Gene (SDH) Mutations In Renal Cell Carcinoma (RCC): A Systematic Review.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31579262","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33502949","id":"PMC_33502949","title":"Suppression of lncRNA HOTAIR alleviates RCC angiogenesis through regulating miR-126/EGFL7 axis.","date":"2021","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33502949","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18247046","id":"PMC_18247046","title":"Characterization of plant XRCC1 and its interaction with proliferating cell nuclear antigen.","date":"2008","source":"Planta","url":"https://pubmed.ncbi.nlm.nih.gov/18247046","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21636980","id":"PMC_21636980","title":"Disconnecting XRCC1 and DNA ligase III.","date":"2011","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21636980","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26587829","id":"PMC_26587829","title":"Infiltrating T cells promote renal cell carcinoma (RCC) progression via altering the estrogen receptor β-DAB2IP signals.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26587829","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28107702","id":"PMC_28107702","title":"C1QBP Regulates YBX1 to Suppress the Androgen Receptor (AR)-Enhanced RCC Cell Invasion.","date":"2017","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28107702","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18474019","id":"PMC_18474019","title":"New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects.","date":"2008","source":"Reviews on recent clinical trials","url":"https://pubmed.ncbi.nlm.nih.gov/18474019","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21643959","id":"PMC_21643959","title":"Impact of DNA repair genes polymorphism (XPD and XRCC1) on the risk of breast cancer in Egyptian female patients.","date":"2011","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21643959","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40680722","id":"PMC_40680722","title":"YTHDC1 lactylation regulates its phase separation to enhance target mRNA stability and promote RCC progression.","date":"2025","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/40680722","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32207384","id":"PMC_32207384","title":"Circular RNA circMTO1 Suppresses RCC Cancer Cell Progression via miR9/LMX1A Axis.","date":"2020","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/32207384","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29051029","id":"PMC_29051029","title":"Recent advances in localized RCC: A focus on VEGF and immuno-oncology therapies.","date":"2017","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29051029","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35546143","id":"PMC_35546143","title":"TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35546143","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21794068","id":"PMC_21794068","title":"Morbidity of tumour enucleation for renal cell carcinoma (RCC): results of a single-centre prospective study.","date":"2011","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/21794068","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28656260","id":"PMC_28656260","title":"Oncogenic miR-23a-5p is associated with cellular function in RCC.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28656260","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30362960","id":"PMC_30362960","title":"XRCC1 gene polymorphisms and risk of neuroblastoma in Chinese children.","date":"2018","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/30362960","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30816207","id":"PMC_30816207","title":"Identification of an XRCC1 DNA binding activity essential for retention at sites of DNA damage.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30816207","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30446622","id":"PMC_30446622","title":"Domain analysis of PNKP-XRCC1 interactions: Influence of genetic variants of XRCC1.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30446622","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26271249","id":"PMC_26271249","title":"Genetic polymorphisms in XRCC1 genes and colorectal cancer susceptibility.","date":"2015","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26271249","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21388825","id":"PMC_21388825","title":"The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach?","date":"2011","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21388825","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34090649","id":"PMC_34090649","title":"Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC.","date":"2021","source":"Seminars in radiation oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34090649","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28315507","id":"PMC_28315507","title":"Polymorphisms and mutations in GSTP1, RAD51, XRCC1 and XRCC3 genes in breast cancer patients.","date":"2017","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/28315507","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26341653","id":"PMC_26341653","title":"First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial.","date":"2015","source":"Cardiovascular and interventional radiology","url":"https://pubmed.ncbi.nlm.nih.gov/26341653","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32426369","id":"PMC_32426369","title":"XRCC1 Is a Promising Predictive Biomarker and Facilitates Chemo-Resistance in Gallbladder Cancer.","date":"2020","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/32426369","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36510217","id":"PMC_36510217","title":"Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy.","date":"2022","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/36510217","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20577654","id":"PMC_20577654","title":"XRCC1, but not APE1 and hOGG1 gene polymorphisms is a risk factor for pterygium.","date":"2010","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/20577654","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19634112","id":"PMC_19634112","title":"Effect of polymorphisms in XRCC1, CCND1 and GSTM1 and tobacco exposure as risk modifier for oral leukoplakia.","date":"2009","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/19634112","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35778544","id":"PMC_35778544","title":"PARP1 and XRCC1 exhibit a reciprocal relationship in genotoxic stress response.","date":"2022","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/35778544","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29552790","id":"PMC_29552790","title":"Haplotype analysis of XRCC1 gene polymorphisms and the risk of thyroid carcinoma.","date":"2018","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29552790","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25245010","id":"PMC_25245010","title":"Association between XRCC1 polymorphisms and glioma risk among Chinese population.","date":"2014","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25245010","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2692268","id":"PMC_2692268","title":"Current state of MRI in renal mass diagnosis and staging of RCC.","date":"1989","source":"Urologic radiology","url":"https://pubmed.ncbi.nlm.nih.gov/2692268","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39040058","id":"PMC_39040058","title":"CXCL3/TGF-β-mediated crosstalk between CAFs and tumor cells augments RCC progression and sunitinib resistance.","date":"2024","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/39040058","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36823017","id":"PMC_36823017","title":"The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis.","date":"2023","source":"Clinical genitourinary cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36823017","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22614155","id":"PMC_22614155","title":"CD133 expression in renal cell carcinoma (RCC) is correlated with nuclear hypoxia-inducing factor 1α (HIF-1α).","date":"2012","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22614155","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25944973","id":"PMC_25944973","title":"Vimentin 3, the new hope, differentiating RCC versus oncocytoma.","date":"2015","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/25944973","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30744807","id":"PMC_30744807","title":"XRCC1 deficiency correlates with increased DNA damage and male infertility.","date":"2019","source":"Mutation research. Genetic toxicology and environmental mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30744807","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32214837","id":"PMC_32214837","title":"Association of XRCC1, XRCC2 and XRCC3 Gene Polymorphism with Esophageal Cancer Risk.","date":"2020","source":"Clinical and experimental gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/32214837","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17696747","id":"PMC_17696747","title":"XRCC1 and XPD gene polymorphisms in a South Indian population.","date":"2007","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/17696747","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20458329","id":"PMC_20458329","title":"Immunologic mechanisms in RCC and allogeneic renal transplant rejection.","date":"2010","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/20458329","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17081983","id":"PMC_17081983","title":"Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17081983","citation_count":2861,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7545953","id":"PMC_7545953","title":"The 1993-94 Généthon human genetic linkage map.","date":"1994","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7545953","citation_count":2146,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24292625","id":"PMC_24292625","title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.","date":"2013","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24292625","citation_count":1480,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15635413","id":"PMC_15635413","title":"Nucleolar proteome dynamics.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/15635413","citation_count":934,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9584196","id":"PMC_9584196","title":"XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9584196","citation_count":786,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8978692","id":"PMC_8978692","title":"Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8978692","citation_count":644,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9485007","id":"PMC_9485007","title":"Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9485007","citation_count":640,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16713569","id":"PMC_16713569","title":"A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16713569","citation_count":610,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11948190","id":"PMC_11948190","title":"Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11948190","citation_count":574,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15498778","id":"PMC_15498778","title":"Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15498778","citation_count":556,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14500814","id":"PMC_14500814","title":"A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage.","date":"2003","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/14500814","citation_count":548,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11163244","id":"PMC_11163244","title":"XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair.","date":"2001","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11163244","citation_count":506,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19661379","id":"PMC_19661379","title":"Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1.","date":"2009","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/19661379","citation_count":496,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8264637","id":"PMC_8264637","title":"An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8264637","citation_count":437,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16221808","id":"PMC_16221808","title":"Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review.","date":"2005","source":"American journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/16221808","citation_count":431,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11532866","id":"PMC_11532866","title":"XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects.","date":"2001","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/11532866","citation_count":404,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15260972","id":"PMC_15260972","title":"AP endonuclease-independent DNA base excision repair in human cells.","date":"2004","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/15260972","citation_count":403,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10783319","id":"PMC_10783319","title":"Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells.","date":"2000","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/10783319","citation_count":392,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11707423","id":"PMC_11707423","title":"XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11707423","citation_count":392,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2247054","id":"PMC_2247054","title":"Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2247054","citation_count":368,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49344,"output_tokens":4728,"usd":0.109476},"stage2":{"model":"claude-opus-4-6","input_tokens":8256,"output_tokens":4445,"usd":0.228607},"total_usd":0.686252,"stage1_batch_id":"msgbatch_01BparvgRZ9S2LMidvaoo86K","stage2_batch_id":"msgbatch_01NkBfv9SVZWthhS7j6mU6G3","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":62163,"output_tokens":6839,"usd":0.144537},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":10841,"output_tokens":3262,"usd":0.203632}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"The C-terminal 96 amino acids of XRCC1 are necessary and sufficient for direct interaction with DNA ligase III (the 103 kDa isoform), while the C-terminal 148 amino acids of DNA ligase III contain the XRCC1 binding site; only the 103 kDa isoform (not the testis-specific 96 kDa isoform) interacts with XRCC1, implying isoform-specific roles in base excision repair.\",\n      \"method\": \"Far Western blotting and affinity precipitation with subcloned XRCC1 and DNA ligase III fragments; antipeptide antibodies confirming in vivo occurrence\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro domain mapping with multiple complementary biochemical methods, foundational paper with 226 citations\",\n      \"pmids\": [\"9136882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"XRCC1 co-localizes with PCNA at DNA replication foci exclusively in S phase, physically interacts with PCNA in vivo (shown by FRET and co-IP), and the interaction is mediated directly by XRCC1 residues 166–310, suggesting XRCC1 is sequestered to replication factories to facilitate single-strand break repair in S phase.\",\n      \"method\": \"Co-immunoprecipitation, FRET analysis, in vitro biochemical interaction mapping with XRCC1 deletion fragments, fluorescence microscopy of replication foci\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (FRET, Co-IP, in vitro binding) in a single study with functional context\",\n      \"pmids\": [\"15107487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Casein kinase 2 (CK2) is the major kinase that phosphorylates XRCC1 in human cell extracts; CK2-mediated phosphorylation is required for XRCC1–DNA ligase IIIα complex stability, and siRNA knockdown of CK2 reduces XRCC1 phosphorylation, destabilizes the complex, reduces Lig III levels, and causes accumulation of DNA strand breaks.\",\n      \"method\": \"Unbiased kinase activity assay in cell extracts, site-directed mutagenesis of CK2 phosphorylation sites, siRNA knockdown of CK2, comet assay for strand break measurement\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — unbiased assay identifying kinase, mutagenesis, and RNAi with functional phenotype in single study\",\n      \"pmids\": [\"20471329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The phosphate-binding pocket within the central BRCT1 domain of XRCC1 selectively binds poly(ADP-ribose) (PAR) at low ADP-ribosylation levels and promotes interaction with cellular PARP1; this pocket is required for XRCC1 accumulation at DNA damage sites (UVA laser, H2O2, PCNA foci) and for XRCC1-dependent acceleration of single-strand break repair, base excision repair, and cell survival.\",\n      \"method\": \"Mutagenesis of PAR-binding pocket, EGFP-XRCC1 live-cell imaging at laser-induced damage, co-immunoprecipitation with PARP1, clonogenic survival and BER assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis combined with live imaging, Co-IP, and functional repair assays in a single study\",\n      \"pmids\": [\"26130715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Biallelic loss-of-function mutations in human XRCC1 cause reduced single-strand break repair and elevated protein ADP-ribosylation (PARP1 hyperactivation); genetic deletion of Parp1 rescued cerebellar ADP-ribose levels, reduced loss of cerebellar neurons, and reduced ataxia in Xrcc1-defective mice, identifying PARP1 hyperactivation as a mechanism by which XRCC1 deficiency triggers neuropathology.\",\n      \"method\": \"Patient-derived cell analysis, mouse genetic epistasis (Xrcc1 KO × Parp1 KO), ADP-ribosylation biochemistry, neuronal cell counting, behavioral ataxia scoring\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with multiple orthogonal endpoints; replicated in human patient cells and mouse model\",\n      \"pmids\": [\"28002403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Either PARP1 or PARP2 alone is sufficient for near-normal XRCC1 (and PNKP) recruitment to oxidative single-strand breaks; loss of both PARP1 and PARP2 (but not either alone or PARP3 deletion) greatly reduces XRCC1 chromatin binding after H2O2, and very low levels of ADP-ribosylation (synthesized by either enzyme) are sufficient to drive XRCC1 recruitment.\",\n      \"method\": \"Isogenic human diploid PARP1/PARP2/PARP3 knockout cells, chromatin fractionation, live imaging of XRCC1 at oxidative SSBs, PARP inhibitor titration\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean isogenic KO cell panel with multiple methods; strong mechanistic conclusion about PAR threshold for XRCC1 recruitment\",\n      \"pmids\": [\"27965414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SIRT1 deacetylates XRCC1 at lysine residues K260, K298, and K431, preventing β-TrCP E3 ligase-mediated poly-ubiquitination and proteasomal degradation of XRCC1; mutations at these three lysine sites abrogate interaction with β-TrCP and extend XRCC1 protein half-life.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis of lysine acetylation sites, mass spectrometry identification of modification sites, ubiquitination assays, protein half-life measurements\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — MS identification of sites plus mutagenesis and ubiquitination assays with multiple orthogonal methods\",\n      \"pmids\": [\"31043584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"XRCC1 assembles complexes containing DNA polymerase β and DNA ligase III that prevent excessive PARP1 engagement ('trapping') on BER intermediates; in XRCC1-deficient cells, PARP1 becomes trapped on BER intermediates (similar to PARP inhibitor treatment), making intermediates inaccessible to DNA polymerase β and blocking repair; PARP1 deletion rescues BER and resistance to base damage in XRCC1-/- cells.\",\n      \"method\": \"XRCC1 KO cell lines (including patient fibroblasts), PARP1 trapping assays, DNA polymerase β accessibility assays, genetic rescue by PARP1 deletion, clonogenic survival after base damage\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — clean KO with biochemical trapping assay, patient cells, and genetic rescue; multiple orthogonal methods\",\n      \"pmids\": [\"34102106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"XRCC1 is required for rapid recovery of transcription following DNA base damage; loss of XRCC1 causes aberrant PARP1 activity during BER, which promotes excessive recruitment and activity of the ubiquitin protease USP3, reducing monoubiquitinated histones important for transcriptional regulation; inhibition or deletion of PARP1 or USP3 restores transcriptional recovery in XRCC1-/- cells.\",\n      \"method\": \"XRCC1 KO human cells, Xrcc1-/- mouse neurons, patient-derived fibroblasts, transcription recovery assays, USP3 KO/inhibition, histone ubiquitination analysis, genetic rescue experiments\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with mechanistic pathway dissection, multiple cell systems including patient-derived and mouse neurons\",\n      \"pmids\": [\"34811483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"XRCC1 contains a central DNA binding domain (CDB, residues 219–415) encompassing its first BRCT domain; alanine substitution within the CDB disrupts DNA binding in vitro and significantly reduces XRCC1 retention (but not initial recruitment) at DNA damage sites, with reduced retention associated with an increased rate of repair.\",\n      \"method\": \"Domain deletion/alanine mutagenesis, in vitro DNA binding assays, laser microirradiation with live-cell imaging of EGFP-XRCC1 retention\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis combined with in vitro binding and live-cell retention assays\",\n      \"pmids\": [\"30816207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Phosphorylated XRCC1 stimulates PNKP by binding to the PNKP FHA domain (with the interaction extending beyond residues 515–526); XRCC1 residues 166–436 bind tightly to PNKP, efficiently activating its kinase activity; XRCC1 SNP variants R194W and R280H show considerably weaker PNKP binding and severely reduced stimulation of PNKP, leading to reduced PNKP recruitment to damaged DNA in cells expressing these variants.\",\n      \"method\": \"In vitro binding assays with XRCC1 fragments, PNKP kinase activity assays, laser microirradiation with live-cell imaging of PNKP recruitment, SNP variant comparison\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro enzymatic assays with domain mapping, mutagenesis, and live-cell imaging; multiple orthogonal methods\",\n      \"pmids\": [\"30446622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"XRCC1 is required for muscle differentiation: caspase-triggered XRCC1 repair foci form rapidly in differentiating myonuclei and then dissipate; skeletal myoblast-specific deletion of Xrcc1 does not affect cell growth but causes sustained DNA damage, impaired myofiber development, and perinatal lethality.\",\n      \"method\": \"Conditional myoblast-specific Xrcc1 KO mouse, XRCC1 repair foci imaging in differentiating cells, DNA damage assays (γH2AX), developmental/histological analysis\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO with specific cellular phenotype (myofiber development) and in vivo lethality, supported by live-cell imaging\",\n      \"pmids\": [\"27462438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"XRCC1 forms an active repair complex with POLQ (DNA polymerase theta) and MRE11 that supports alternative end-joining (alt-EJ) activity in vitro; BRCA2 limits XRCC1 recruitment and complex formation to suppress alt-EJ at stalled replication forks; without BRCA2 fork protection, XRCC1 promotes MRE11-dependent fork resection and restart at the cost of increased genome instability.\",\n      \"method\": \"In vitro alt-EJ reconstitution assay with XRCC1/POLQ/MRE11, co-immunoprecipitation, BRCA2-depleted cell lines, fork resection and restart assays, chromosome aberration analysis\",\n      \"journal\": \"NAR cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro reconstitution combined with cell-based genetic epistasis, but single lab study\",\n      \"pmids\": [\"32776008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The primary biochemical defect associated with XRCC1 deficiency is a ~2–4-fold reduction in nick ligation activity; XRCC1-deficient cell extracts show normal base excision activity for multiple DNA lesions, normal abasic site incision, and normal gap-filling, demonstrating XRCC1's main biochemical role is at the ligation step of BER/SSBR.\",\n      \"method\": \"Whole-cell extract repair assays for specific BER steps, DNA damage measurement by GC-MS and other techniques, using XRCC1-deficient CHO EM9 cells\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic in vitro reconstitution assays across all BER steps with defined cell lines, clearly placing XRCC1's biochemical function\",\n      \"pmids\": [\"16245950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PARP1 and XRCC1 have a reciprocal relationship: recruitment of each protein to DNA damage sites requires the presence of the other; XRCC1 KO cells show hypersensitivity to topoisomerase I inhibitor camptothecin and impaired DNA repair that can be partially rescued by additional PARP1 deletion or pharmacological PARP inhibition.\",\n      \"method\": \"PARP1 KO, XRCC1 KO, and double KO HeLa cells; PARylation assays; NAD+ measurement; clonogenic survival; cell cycle and cell death analysis; comet assay\",\n      \"journal\": \"Cell biology and toxicology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean isogenic KO cell panel with multiple orthogonal endpoints and genetic rescue\",\n      \"pmids\": [\"35778544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"KDM5B demethylates H3K4 to facilitate recruitment of XRCC1 to DNA damage sites; KDM5B is stabilized by the molecular chaperone HSP90 (shown by co-IP), and HSP90 inhibition induces KDM5B degradation, blocking XRCC1 recruitment and reversing cisplatin resistance.\",\n      \"method\": \"Mass spectrometry and co-immunoprecipitation for KDM5B–HSP90 interaction, KDM5B knockdown/overexpression, chemical inhibition of H3K4 demethylases, co-localization of XRCC1 and γH2AX, in vitro and in vivo cisplatin sensitivity assays\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — MS plus Co-IP for interaction, functional rescue; single lab with moderate mechanistic depth for XRCC1 recruitment specifically\",\n      \"pmids\": [\"29989047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Inactivation of XRCC1 and DNA Ligase III in the developing nervous system yields distinct phenotypes, indicating non-redundant roles; LIG3 function is central to mitochondrial DNA maintenance rather than nuclear DNA repair, whereas XRCC1-mediated nuclear repair relies primarily on DNA Ligase 1 rather than DNA Ligase III.\",\n      \"method\": \"Nervous system-specific conditional KO mice for XRCC1 and LIG3; phenotypic comparison; mitochondrial DNA analysis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with clear phenotypic separation; mechanistic conclusion supported by KO phenotypes\",\n      \"pmids\": [\"21636980\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"XRCC1 is a scaffold protein with no intrinsic enzymatic activity that orchestrates DNA single-strand break repair (SSBR) and base excision repair (BER) by assembling multi-protein complexes: its N-terminal domain binds DNA polymerase β, its central BRCT1 domain binds poly(ADP-ribose) (synthesized by PARP1 or PARP2) to mediate damage recruitment and retention, and its C-terminal BRCT2 domain binds and stabilizes DNA ligase IIIα (the 103 kDa isoform only); XRCC1 is phosphorylated by CK2 to maintain the XRCC1–LigIII complex, and deacetylated by SIRT1 to prevent β-TrCP-mediated proteasomal degradation; critically, XRCC1 restrains PARP1 activity during BER so that excessive PARP1 engagement ('trapping') on repair intermediates does not block repair or suppress transcription via the USP3–histone monoubiquitination axis, and loss of this PARP1 regulation drives neuropathology in XRCC1-deficient humans and mice.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"Molecular cloning of XRCC1 established it as a 633-amino-acid protein (69.5 kDa) required for efficient DNA single-strand break repair; CHO mutant EM9 cells lacking XRCC1 show reduced strand-break rejoining, elevated sister chromatid exchange, and sensitivity to alkylating agents and ionizing radiation.\",\n      \"method\": \"cDNA cloning, complementation of CHO EM9 mutant, strand-break repair kinetics, cell survival, SCE assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original gene cloning with functional complementation, multiple orthogonal assays\",\n      \"pmids\": [\"2247054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"XRCC1 physically interacts with DNA ligase III in human cells; XRCC1 is required for normal levels of DNA ligase III activity, implicating this ligase in base excision repair.\",\n      \"method\": \"Affinity chromatography (His-tagged XRCC1 co-purification), DNA ligase III activity assay in EM9 cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — affinity purification co-purification with functional readout, foundational study >400 citations\",\n      \"pmids\": [\"8264637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"XRCC1 directly interacts with DNA polymerase β (pol β) via residues 84–183 in its N-terminal region; the C-terminal region binds DNA ligase III. XRCC1 suppresses strand displacement by pol β during single-nucleotide BER reconstitution, allowing efficient nick ligation. XRCC1 thus functions as a scaffold protein without catalytic activity.\",\n      \"method\": \"BER reconstitution with purified recombinant human proteins, far Western blotting, affinity precipitation, yeast two-hybrid, gel retardation (supershift) assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution + multiple orthogonal interaction methods, domain mapping, highly cited\",\n      \"pmids\": [\"8978692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Only the 103 kDa isoform of DNA ligase III (not the testis-specific 96 kDa isoform) interacts with XRCC1; the C-terminal 96 amino acids of XRCC1 are necessary and sufficient for the interaction, and the C-terminal 148 amino acids of DNA ligase III contain the XRCC1-binding site.\",\n      \"method\": \"Far Western blotting, affinity precipitation of subcloned XRCC1 and DNA ligase III fragments, antipeptide antibodies\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — domain mapping with multiple orthogonal methods, >200 citations\",\n      \"pmids\": [\"9136882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"XRCC1 physically associates with PARP-1 via its central BRCT I domain (amino acids 301–402); XRCC1 overexpression dramatically decreases PARP-1 activity in vivo, identifying XRCC1 as a negative regulator of PARP-1 and placing PARP-1 in a BER multiprotein complex with XRCC1, pol β, and DNA ligase III.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation in mammalian cells, PARP-1 activity assay after XRCC1 overexpression\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — yeast two-hybrid + mammalian co-IP + functional assay, >780 citations\",\n      \"pmids\": [\"9584196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"XRCC1 interacts with polynucleotide kinase (PNK) and stimulates PNK's DNA kinase and DNA phosphatase activities at damaged DNA termini; XRCC1, pol β, PNK, and DNA ligase III form multiprotein complexes in human cell extracts that together repair oxidative/ionizing-radiation-type single-strand breaks.\",\n      \"method\": \"Co-immunoprecipitation, in vitro DNA kinase/phosphatase activity assays, multi-protein SSB repair assay in cell extracts\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution + enzyme activity assay + co-IP, >500 citations\",\n      \"pmids\": [\"11163244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"XRCC1 physically interacts with APE1 and stimulates APE1 endonuclease activity; a truncated APE1 lacking the first 35 amino acids retains catalytic activity but cannot bind XRCC1 and is not stimulated by it. XRCC1-deficient CHO cells have reduced capacity to initiate repair of abasic sites, corrected by XRCC1 expression.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, APE1 activity assay with recombinant proteins, AP-site repair assay in XRCC1-deficient cells\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods including activity assay and cellular complementation, >390 citations\",\n      \"pmids\": [\"11707423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PARP-2 interacts with XRCC1 (as well as pol β and DNA ligase III); XRCC1 negatively regulates PARP-2 activity similarly to PARP-1. PARP-2-deficient cells show delayed DNA strand-break resealing after alkylation damage, demonstrating a functional role for PARP-2 in BER alongside XRCC1.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, PARP-2 activity assay, PARP-2 knockout mouse cells with strand-break repair kinetics\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — protein interaction, activity assay, and KO cell repair assay; >570 citations\",\n      \"pmids\": [\"11948190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PARP-1 is required for assembly/stability of XRCC1 nuclear foci at sites of oxidative DNA damage; XRCC1 foci co-localize with poly(ADP-ribose) synthesis and fail to form in PARP-1-null MEFs or when the XRCC1 BRCT I domain is mutated, demonstrating that PARP-1-generated PAR mediates XRCC1 recruitment.\",\n      \"method\": \"Immunofluorescence microscopy of XRCC1 foci after H2O2, PARP-1 KO MEFs, BRCT I domain point mutants of XRCC1\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — live-cell imaging + genetic KO + domain mutants, >540 citations\",\n      \"pmids\": [\"14500814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"XRCC1 co-localizes with PCNA at DNA replication foci in S phase and physically interacts with PCNA in vivo; in vitro the interaction is mediated by XRCC1 residues 166–310. This suggests XRCC1 is recruited to replication factories via PCNA to facilitate SSBR during S phase.\",\n      \"method\": \"Immunofluorescence co-localization, FRET analysis, co-immunoprecipitation, in vitro binding with XRCC1 fragments\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (FRET, co-IP, in vitro mapping), >160 citations\",\n      \"pmids\": [\"15107487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PARP-1 and the XRCC1–DNA ligase III complex participate in an alternative, DNA-PK-independent pathway for DNA double-strand break end-joining; PARP-1 provides synapsis activity and XRCC1–ligase III provides ligation in this alt-EJ route.\",\n      \"method\": \"In vitro synapsis and end-joining two-step assay with nuclear extracts and recombinant proteins, PARP inhibitor cytotoxicity, DSB repair kinetics\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution with purified proteins, >550 citations\",\n      \"pmids\": [\"15498778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The primary biochemical defect in XRCC1-deficient cells is impaired nick ligation (~2–4-fold reduction); base excision (8-oxoG, 5-HC, εA, uracil), AP-site incision, and pol β gap-filling activities are normal in XRCC1-deficient extracts, demonstrating XRCC1's key role is at the ligation step of BER/SSBR.\",\n      \"method\": \"Whole-cell extract BER and SSBR assays, 8-oxoG and AP-site measurement by HPLC/GC-MS in EM9 cells\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic in vitro biochemical dissection of BER steps in XRCC1-deficient extracts\",\n      \"pmids\": [\"16245950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Casein kinase 2 (CK2) is the major kinase phosphorylating XRCC1 in human cell extracts; CK2-mediated phosphorylation stabilizes the XRCC1–DNA ligase IIIα complex, and mutation of CK2 phosphorylation sites or CK2 siRNA knockdown destabilizes the complex, reduces ligase III levels, and causes accumulation of DNA strand breaks.\",\n      \"method\": \"Unbiased kinase activity assay in cell extracts, CK2 siRNA knockdown, CK2-site mutants of XRCC1, co-immunoprecipitation, comet assay\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — kinase identification by biochemical assay + site mutagenesis + genetic knockdown with functional readout\",\n      \"pmids\": [\"20471329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Conditional neural knockout studies reveal that DNA ligase 1 (not ligase III) is the main ligase for XRCC1-mediated nuclear DNA repair; LIG3's essential function is in mitochondrial DNA maintenance, dissociating the cellular roles of XRCC1 and LIG3.\",\n      \"method\": \"Tissue-specific (neural) conditional knockout mice for XRCC1 and LIG3, phenotypic comparison, mitochondrial DNA maintenance assays\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic dissection with mouse KO models revealing distinct in vivo roles\",\n      \"pmids\": [\"21636980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The phosphate-binding pocket of the XRCC1 BRCT1 domain selectively binds poly(ADP-ribose) at low PAR levels and is required for interaction with cellular PARP-1, XRCC1 accumulation at UVA/H2O2 damage sites and PCNA foci, and XRCC1-dependent acceleration of SSBR, BER, and cell survival after DNA damage.\",\n      \"method\": \"PAR-binding assays with BRCT1 mutants, co-immunoprecipitation with PARP-1, EGFP-XRCC1 live-cell damage-recruitment assays, BER/SSBR reporter assays, clonogenic survival\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — domain mutagenesis + binding assay + cellular recruitment + functional repair assays, multiple orthogonal methods\",\n      \"pmids\": [\"26130715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Biallelic loss-of-function mutations in human XRCC1 cause ocular motor apraxia, axonal neuropathy, and progressive cerebellar ataxia, associated with reduced SSBR and elevated protein ADP-ribosylation (PARP hyperactivation). Genetic deletion of Parp1 in Xrcc1-deficient mice rescues cerebellar ADP-ribose levels, reduces cerebellar neuron loss, and alleviates ataxia, identifying PARP1 hyperactivation as the pathogenic mechanism.\",\n      \"method\": \"Patient cell studies (SSBR rates, PAR levels), Xrcc1/Parp1 double-KO mouse model, cerebellar neuron counting, ADP-ribosylation quantification\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human genetics + mouse double-KO genetic rescue with defined molecular and cellular phenotypes, >200 citations\",\n      \"pmids\": [\"28002403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"XRCC1 is an indispensable mediator of muscle differentiation: caspase-triggered DNA strand breaks during myoblast differentiation are rapidly followed by XRCC1 repair foci formation in myonuclei, and skeletal-myoblast-specific deletion of Xrcc1 does not affect cell growth but causes perinatal lethality with sustained DNA damage and impaired myofiber development.\",\n      \"method\": \"Conditional Xrcc1 knockout in skeletal myoblasts, immunofluorescence of XRCC1 repair foci, γH2AX staining, myofiber morphology analysis\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific KO with defined phenotype linked to XRCC1 repair foci dynamics\",\n      \"pmids\": [\"27462438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Either PARP1 or PARP2 alone is sufficient for near-normal XRCC1 recruitment to oxidative single-strand breaks; loss of both PARP1 and PARP2 together is required to greatly reduce or ablate XRCC1 chromatin binding after H2O2. Very low levels of ADP-ribosylation (by either enzyme) are sufficient for XRCC1 recruitment. PNKP recruitment similarly requires PARP1/2 redundancy.\",\n      \"method\": \"Isogenic PARP1/PARP2/PARP3 single and double KO human diploid cells, H2O2-induced XRCC1 and PNKP chromatin fractionation, PARP inhibitor dose-response\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isogenic genetic knockouts with quantitative chromatin binding assay, multiple combinations\",\n      \"pmids\": [\"27965414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"KDM5B demethylates H3K4 at DNA damage sites and facilitates XRCC1 recruitment; increased KDM5B in cisplatin-resistant gastric cancer cells promotes H3K4 demethylation, enabling XRCC1 co-localization with γH2AX. HSP90 stabilizes KDM5B via direct complex formation. KDM5B or HSP90 inhibition blocks XRCC1 recruitment to damage, restoring drug sensitivity.\",\n      \"method\": \"Co-immunoprecipitation, γH2AX/XRCC1 co-localization imaging, KDM5B knockdown/overexpression, JIB-04 inhibitor, HSP90 inhibitor 17-AAG, mass spectrometry\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — co-IP + imaging + inhibitor studies in a single lab; chromatin-level mechanism proposed\",\n      \"pmids\": [\"29989047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PNKP interacts with XRCC1 through two distinct interfaces: the PNKP FHA domain binds phosphorylated XRCC1 (extending beyond residues 515–526), and an XRCC1 fragment (residues 166–436) binds the PNKP catalytic domain and tightly activates PNKP kinase activity. XRCC1 SNP variants R194W and R280H show substantially weaker PNKP binding and severely reduced PNKP stimulation, and cells expressing these variants show reduced PNKP recruitment to laser-induced DNA damage.\",\n      \"method\": \"In vitro binding and PNKP kinase activity assays with recombinant XRCC1 fragments and SNP variants, laser microirradiation/live-cell recruitment imaging\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — enzyme activity assay + domain mapping + cell-based recruitment with disease-relevant SNP variants\",\n      \"pmids\": [\"30446622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SIRT1 deacetylates XRCC1 at lysines K260, K298, and K431, preventing β-TrCP-mediated ubiquitination and proteasomal degradation of XRCC1. Mutations at these three sites abrogate β-TrCP interaction and prolong XRCC1 half-life; SIRT1 knockdown reduces XRCC1 stability and enhances DNA damage, contributing to chemoresistance.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, site-directed mutagenesis, cycloheximide chase (half-life), SIRT1 KD by siRNA/inhibitor\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — PTM identification by site mutagenesis + stability assay + E3 ligase identification\",\n      \"pmids\": [\"31043584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"XRCC1 contains a central DNA-binding domain (CDB, residues 219–415) encompassing the BRCT1 domain that lacks specificity for nicked/gapped DNA. Alanine substitution of CDB residues abolishes DNA binding in vitro and significantly reduces XRCC1 retention (but not initial recruitment) at DNA damage sites, and reduced retention is associated with an increased rate of repair, suggesting DNA binding regulates dwell time at damage.\",\n      \"method\": \"Electrophoretic mobility shift assay, alanine scanning mutagenesis, live-cell XRCC1-GFP retention assay at laser-induced damage sites\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — domain mapping by mutagenesis + in vitro DNA binding + live-cell functional imaging\",\n      \"pmids\": [\"30816207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"After replication stress, XRCC1 forms an active repair complex with POLQ and MRE11 that supports alternative end-joining (alt-EJ) in vitro; BRCA2 normally limits XRCC1 recruitment to suppress alt-EJ at stalled forks. Without BRCA2 fork protection, XRCC1 enables replication completion via MRE11-dependent fork resection and restart, at the cost of increased genome instability.\",\n      \"method\": \"In vitro alt-EJ reconstitution with XRCC1/POLQ/MRE11, BRCA2-XRCC1 co-depletion, fork restart/resection assays, chromosome aberration analysis\",\n      \"journal\": \"NAR cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro reconstitution + genetic epistasis in BRCA2-deficient cells; single lab\",\n      \"pmids\": [\"32776008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"XRCC1 prevents 'toxic PARP1 trapping' during BER: protein complexes of pol β and DNA ligase III assembled by XRCC1 prevent excessive PARP1 engagement at BER intermediates. In XRCC1-deficient cells (and patient fibroblasts), PARP1 becomes trapped on BER intermediates—similar to PARP-inhibitor trapping—blocking pol β access and impeding repair. PARP1 deletion rescues BER and resistance to base damage in XRCC1−/− cells.\",\n      \"method\": \"Trapping assay (PARP1 chromatin fractionation), BER intermediate accumulation assay, PARP1-XRCC1 double KO cells, patient-derived fibroblasts, base damage sensitivity (clonogenic)\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic trapping assay + genetic double KO rescue + patient cells + multiple orthogonal assays\",\n      \"pmids\": [\"34102106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"XRCC1-deficient human cells and patient fibroblasts fail to recover transcription after DNA base damage due to excessive/aberrant PARP1 activity during BER. This aberrant PARP1 activity promotes excessive recruitment of ubiquitin protease USP3, which reduces monoubiquitinated histones required for normal transcription. Inhibition or deletion of PARP1 or USP3 restores transcriptional recovery in XRCC1−/− cells.\",\n      \"method\": \"Transcription recovery assay (EU incorporation) in XRCC1 KO cells, patient fibroblasts, Xrcc1−/− neurons; PARP1 and USP3 KO/inhibition rescue experiments; ubiquitin-histone western blotting\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KOs + patient cells + mouse neurons + specific pathway placement via USP3/histone ubiquitination mechanism\",\n      \"pmids\": [\"34811483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"XRCC1 and PARP1 exhibit a reciprocal relationship at DNA damage sites: recruitment of each protein is impeded in the absence of the other. XRCC1 KO cells show hypersensitivity (excess NAD+ depletion, cytotoxicity) to topoisomerase I inhibitor camptothecin compared to PARP1 KO cells, and additional PARP1 deletion or pharmacological PARP inhibition rescues this hypersensitivity and partially restores DNA repair in XRCC1 KO cells.\",\n      \"method\": \"PARP1 KO, XRCC1 KO, and PARP1/XRCC1 double KO HeLa cells; PARylation assay, NAD+ quantification, clonogenic survival, cell-cycle analysis, comet assay\",\n      \"journal\": \"Cell biology and toxicology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isogenic genetic KO panel with multiple cellular endpoints demonstrating reciprocal regulation\",\n      \"pmids\": [\"35778544\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"XRCC1 is a scaffolding protein without intrinsic catalytic activity that coordinates DNA single-strand break repair (SSBR) and base excision repair (BER) by assembling multi-enzyme complexes: its N-terminal domain binds DNA polymerase β (residues 84–183), its central BRCT1 domain binds poly(ADP-ribose) (PAR) synthesized by PARP1/PARP2 to enable damage-site recruitment, and its C-terminal region binds DNA ligase IIIα; it also stimulates PNK and APE1 activities, is stabilized by CK2-mediated phosphorylation and SIRT1-mediated deacetylation (preventing β-TrCP ubiquitination), and critically functions as an 'anti-trapper' that prevents toxic PARP1 engagement on BER intermediates—loss of XRCC1 leads to PARP1 hyperactivation, transcriptional suppression via USP3-mediated histone de-ubiquitination, and neurodegeneration rescued by PARP1 deletion.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"XRCC1 is a scaffold protein central to DNA single-strand break repair (SSBR) and base excision repair (BER), lacking intrinsic enzymatic activity but coordinating the assembly and activity of repair complexes at damaged DNA. Its N-terminal domain binds DNA polymerase β, a central BRCT1 domain binds poly(ADP-ribose) synthesized by PARP1 or PARP2 to mediate recruitment to damage sites, and its C-terminal BRCT2 domain binds and stabilizes the 103 kDa isoform of DNA ligase IIIα—the principal biochemical defect in XRCC1-deficient cells being reduced nick ligation [PMID:9136882, PMID:16245950, PMID:26130715, PMID:27965414]. XRCC1 restrains excessive PARP1 engagement on BER intermediates; in XRCC1-deficient cells, PARP1 trapping blocks polymerase β access to repair sites and suppresses transcriptional recovery via USP3-mediated histone deubiquitination, and genetic deletion of PARP1 rescues these defects including cerebellar neurodegeneration in mice and humans with biallelic XRCC1 loss-of-function mutations [PMID:28002403, PMID:34102106, PMID:34811483]. Protein stability and complex integrity are regulated by CK2 phosphorylation, which maintains the XRCC1–LigIIIα complex, and by SIRT1 deacetylation, which prevents β-TrCP-mediated proteasomal degradation [PMID:20471329, PMID:31043584]. Biallelic loss-of-function mutations in XRCC1 cause a human neurodegenerative disorder characterized by cerebellar ataxia driven by PARP1 hyperactivation [PMID:28002403].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Identifying how XRCC1 physically engages the ligation machinery established it as a BER scaffold: the C-terminal 96 residues directly bind the 103 kDa (but not 96 kDa) isoform of DNA ligase III, defining isoform-specific partnership in nuclear repair.\",\n      \"evidence\": \"Far Western blotting and affinity precipitation with subcloned domain fragments of XRCC1 and DNA ligase III\",\n      \"pmids\": [\"9136882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No information on whether interaction is regulated by post-translational modifications\", \"Structural basis of the BRCT2–LigIII interface not resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrating that XRCC1 co-localizes and physically interacts with PCNA at S-phase replication foci (via residues 166–310) revealed that SSBR is coupled to DNA replication.\",\n      \"evidence\": \"Co-immunoprecipitation, FRET, in vitro binding with deletion fragments, and fluorescence microscopy in human cells\",\n      \"pmids\": [\"15107487\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of disrupting XRCC1–PCNA interaction for replication-associated repair not tested\", \"Whether PCNA binding competes with other XRCC1 interactions is unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Systematically dissecting each BER step in XRCC1-deficient extracts pinpointed the primary biochemical defect as a 2–4-fold reduction in nick ligation, not in base excision, incision, or gap filling, clarifying XRCC1's role as a ligation-stage scaffold.\",\n      \"evidence\": \"Step-by-step in vitro BER assays using XRCC1-deficient CHO EM9 cell extracts\",\n      \"pmids\": [\"16245950\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address whether XRCC1 additionally accelerates earlier BER steps in intact chromatin\", \"Assay performed in CHO cells, not human cells\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identifying CK2 as the kinase responsible for XRCC1 phosphorylation showed how the XRCC1–LigIIIα complex is maintained: CK2 phosphorylation stabilizes the complex, and its loss causes LigIII degradation and DNA strand break accumulation.\",\n      \"evidence\": \"Unbiased kinase activity screen in cell extracts, CK2 site mutagenesis, siRNA knockdown, comet assay\",\n      \"pmids\": [\"20471329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific CK2 phosphorylation sites on XRCC1 responsible for LigIII stabilization not fully mapped\", \"Regulation of CK2 activity at damage sites not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Nervous system-specific KO of XRCC1 versus LIG3 revealed non-redundant roles: LIG3 is essential for mitochondrial DNA maintenance, whereas XRCC1-dependent nuclear repair utilizes DNA Ligase 1 rather than LigIII, redefining the assumed obligate XRCC1–LigIII partnership in vivo.\",\n      \"evidence\": \"Conditional nervous system-specific KO mice for XRCC1 and LIG3 with phenotypic and mitochondrial DNA analysis\",\n      \"pmids\": [\"21636980\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of Ligase 1 recruitment to XRCC1-dependent repair not characterized\", \"Whether this applies outside the nervous system is unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identifying the BRCT1 phosphate-binding pocket as a selective PAR-binding module explained how XRCC1 is recruited to damage sites: even low levels of ADP-ribosylation suffice to drive XRCC1 accumulation, and this pocket is required for SSBR, BER, and cell survival.\",\n      \"evidence\": \"PAR-binding pocket mutagenesis, EGFP-XRCC1 live-cell imaging at laser-induced damage, co-immunoprecipitation with PARP1, clonogenic survival assays\",\n      \"pmids\": [\"26130715\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether XRCC1 discriminates between PAR chain lengths is not resolved\", \"Contribution of other PAR-binding modes outside the pocket not excluded\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Biallelic XRCC1 mutations in humans and cerebellar-specific KO in mice linked XRCC1 deficiency to neurodegeneration via PARP1 hyperactivation: genetic deletion of Parp1 rescued ADP-ribose accumulation, neuronal loss, and ataxia, establishing a causal disease mechanism.\",\n      \"evidence\": \"Patient-derived cell analysis, Xrcc1 KO × Parp1 KO mouse genetic epistasis, ADP-ribosylation biochemistry, neuronal counting, ataxia scoring\",\n      \"pmids\": [\"28002403\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other tissues besides cerebellum are similarly affected by PARP1-dependent toxicity is unknown\", \"Contribution of NAD+ depletion versus PAR signaling to neuronal death not fully dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showing that XRCC1 is required for muscle differentiation—where caspase-triggered strand breaks must be rapidly repaired—extended XRCC1's role beyond generic SSBR to a developmental context, with myoblast-specific KO causing perinatal lethality.\",\n      \"evidence\": \"Conditional myoblast-specific Xrcc1 KO mouse, repair foci imaging in differentiating cells, γH2AX assays\",\n      \"pmids\": [\"27462438\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether XRCC1 participates in differentiation-associated repair in other lineages is not tested\", \"Mechanism linking caspase-induced breaks to XRCC1 foci formation not fully elucidated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Using isogenic PARP1/PARP2/PARP3 KO panels demonstrated that either PARP1 or PARP2 alone suffices for XRCC1 recruitment to oxidative SSBs, but loss of both abolishes recruitment, defining the minimal ADP-ribosylation requirement.\",\n      \"evidence\": \"Isogenic human diploid PARP1/PARP2/PARP3 KO cells, chromatin fractionation, live imaging, PARP inhibitor titration\",\n      \"pmids\": [\"27965414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other ADP-ribosyltransferases can compensate under specific damage conditions is unknown\", \"Quantitative PAR threshold for XRCC1 recruitment not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Mapping the XRCC1–PNKP interaction to residues 166–436 and showing that phosphorylated XRCC1 stimulates PNKP kinase activity revealed how XRCC1 activates end-processing; cancer-associated SNP variants R194W and R280H severely impair this stimulation.\",\n      \"evidence\": \"In vitro binding and PNKP kinase assays with XRCC1 fragments, laser microirradiation with live-cell imaging, SNP variant comparison\",\n      \"pmids\": [\"30446622\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical significance of reduced PNKP stimulation by SNP variants not established in patient samples\", \"Whether other XRCC1 partners compete for the same binding region is not addressed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"SIRT1-mediated deacetylation at K260/K298/K431 was shown to protect XRCC1 from β-TrCP ubiquitin ligase-dependent proteasomal degradation, establishing a post-translational stabilization mechanism independent of CK2 phosphorylation.\",\n      \"evidence\": \"Co-immunoprecipitation, mass spectrometry of acetylation sites, lysine mutagenesis, ubiquitination and protein half-life assays\",\n      \"pmids\": [\"31043584\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SIRT1-mediated regulation is damage-inducible or constitutive is not clear\", \"Interplay between acetylation and CK2 phosphorylation on the same molecule not examined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identifying a central DNA-binding domain (CDB, residues 219–415) that is required for XRCC1 retention—but not initial recruitment—at damage sites distinguished two phases of XRCC1 engagement: PAR-dependent recruitment and DNA-dependent retention.\",\n      \"evidence\": \"Alanine mutagenesis of CDB, in vitro DNA binding assays, laser microirradiation with live-cell retention kinetics\",\n      \"pmids\": [\"30816207\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CDB binding involves specific DNA structures (e.g., nicks, gaps) is unresolved\", \"Overlap of CDB with PNKP and PCNA binding regions raises unresolved questions about binding competition\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Reconstituting an XRCC1–POLQ–MRE11 complex with alternative end-joining activity in vitro, and showing that BRCA2 limits XRCC1 recruitment to suppress alt-EJ at stalled forks, expanded XRCC1's role beyond canonical SSBR/BER to replication fork processing.\",\n      \"evidence\": \"In vitro alt-EJ reconstitution, co-immunoprecipitation, BRCA2-depleted cell lines, fork resection/restart assays, chromosome aberration analysis\",\n      \"pmids\": [\"32776008\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab observation; not independently confirmed\", \"Physiological relevance of XRCC1 in alt-EJ relative to its canonical SSBR/BER role is unclear\", \"Structural basis of XRCC1–POLQ interaction not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing that XRCC1 prevents PARP1 trapping on BER intermediates—analogous to pharmacological PARP inhibitor action—unified the scaffolding and PARP-regulatory functions: without XRCC1, trapped PARP1 blocks Polβ access, and PARP1 deletion rescues BER.\",\n      \"evidence\": \"XRCC1 KO and patient fibroblasts, PARP1 trapping assays, Polβ accessibility assays, genetic rescue by PARP1 deletion, clonogenic survival\",\n      \"pmids\": [\"34102106\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PARP2 trapping also occurs in XRCC1-deficient cells is not tested\", \"Structural basis for how XRCC1 displaces PARP1 from intermediates is unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linking XRCC1 to transcription recovery after base damage via a PARP1→USP3→histone monoubiquitination axis showed that XRCC1 deficiency impairs gene expression, not just strand break resolution, explaining transcriptional pathology in XRCC1-deficient neurons.\",\n      \"evidence\": \"XRCC1 KO human cells, Xrcc1−/− mouse neurons, patient fibroblasts, transcription recovery assays, USP3 KO/inhibition, histone ubiquitination analysis\",\n      \"pmids\": [\"34811483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the PARP1–USP3 axis contributes to pathology in non-neuronal XRCC1-deficient tissues is unknown\", \"Identity of specific genes whose transcription is compromised is not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating reciprocal dependence between PARP1 and XRCC1 for recruitment to damage, and partial rescue of XRCC1 KO hypersensitivity by PARP1 deletion, consolidated the model that unchecked PARP1 is a primary toxicity driver in XRCC1 deficiency.\",\n      \"evidence\": \"PARP1 KO, XRCC1 KO, and double KO HeLa cells; PARylation, NAD+, clonogenic survival, comet assays\",\n      \"pmids\": [\"35778544\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for PARP1's dependence on XRCC1 for its own recruitment is mechanistically unclear\", \"Whether NAD+ depletion or PAR signaling is the primary toxic consequence remains unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Unresolved: the structural mechanism by which XRCC1 displaces trapped PARP1 from BER intermediates, the relative contributions of NAD+ depletion versus aberrant PAR signaling to tissue-specific pathology, and whether XRCC1's role in alternative end-joining has physiological significance.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of XRCC1 at a repair intermediate with PARP1\", \"Tissue-specific regulation of XRCC1 expression and complex assembly poorly understood\", \"XRCC1's contribution to alt-EJ relative to canonical SSBR/BER not quantified in vivo\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 3, 7, 10, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 3, 9, 11]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [1, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 3, 4, 5, 7, 8, 9, 13, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 8]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"complexes\": [\n      \"XRCC1–DNA ligase IIIα complex\",\n      \"XRCC1–DNA polymerase β complex\",\n      \"XRCC1–PNKP complex\"\n    ],\n    \"partners\": [\n      \"LIG3\",\n      \"POLB\",\n      \"PARP1\",\n      \"PARP2\",\n      \"PNKP\",\n      \"PCNA\",\n      \"SIRT1\",\n      \"CSNK2A1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"XRCC1 is a scaffold protein that coordinates DNA single-strand break repair (SSBR) and base excision repair (BER) by assembling multi-enzyme repair complexes at sites of DNA damage. Its N-terminal domain binds DNA polymerase β (residues 84–183), its central BRCT1 domain binds poly(ADP-ribose) synthesized by PARP1/PARP2 to mediate damage-site recruitment, and its C-terminal region binds DNA ligase IIIα; it also stimulates the enzymatic activities of polynucleotide kinase and APE1, with its protein stability regulated by CK2 phosphorylation and SIRT1-mediated deacetylation that prevents β-TrCP ubiquitination [PMID:8978692, PMID:26130715, PMID:11163244, PMID:11707423, PMID:20471329, PMID:31043584]. A critical function of XRCC1 is to act as an anti-trapper that prevents toxic PARP1 engagement on BER intermediates; loss of XRCC1 causes PARP1 hyperactivation leading to transcriptional suppression via USP3-mediated histone de-ubiquitination, NAD+ depletion, and neurodegeneration that is rescued by PARP1 deletion [PMID:34102106, PMID:34811483, PMID:35778544]. Biallelic loss-of-function mutations in human XRCC1 cause ocular motor apraxia, axonal neuropathy, and progressive cerebellar ataxia driven by PARP1 hyperactivation [PMID:28002403].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Cloning XRCC1 established it as a gene essential for single-strand break repair, resolving the molecular identity behind the radiation-sensitive CHO EM9 complementation group and linking it to alkylating-agent sensitivity and elevated sister chromatid exchange.\",\n      \"evidence\": \"cDNA cloning and functional complementation of CHO EM9 cells with strand-break repair kinetics, SCE, and survival assays\",\n      \"pmids\": [\"2247054\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No catalytic activity or interaction partners identified\", \"Mechanism of XRCC1 action in repair unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identification of DNA ligase III and DNA polymerase β as direct XRCC1 partners, with domain mapping, established that XRCC1 is a non-catalytic scaffold that coordinates the ligation and gap-filling steps of BER.\",\n      \"evidence\": \"BER reconstitution with purified proteins, far Western blotting, yeast two-hybrid, and affinity precipitation with domain fragments\",\n      \"pmids\": [\"8264637\", \"8978692\", \"9136882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No information on how XRCC1 is recruited to damage sites\", \"Role of other potential partners unexplored\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Discovery that XRCC1 physically associates with PARP-1 via its BRCT1 domain and negatively regulates PARP-1 activity revealed a regulatory link between damage sensing and scaffold-mediated repair assembly.\",\n      \"evidence\": \"Yeast two-hybrid, co-immunoprecipitation, and PARP-1 activity assay after XRCC1 overexpression\",\n      \"pmids\": [\"9584196\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PARP-1 activity is required for XRCC1 recruitment not yet tested\", \"PARP-2 relationship unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Expansion of the XRCC1 interactome to include PNK and APE1, with demonstration that XRCC1 stimulates their enzymatic activities, established XRCC1 as a hub that accelerates multiple enzymatic steps in SSBR beyond ligation.\",\n      \"evidence\": \"Co-immunoprecipitation, in vitro kinase/phosphatase and endonuclease activity assays, cellular complementation of XRCC1-deficient cells\",\n      \"pmids\": [\"11163244\", \"11707423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for enzymatic stimulation unknown\", \"Relative contributions of each interaction to overall repair rate not quantified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstration that PARP-1-generated poly(ADP-ribose) is required for XRCC1 nuclear focus formation answered how XRCC1 is recruited to damage sites, placing PAR as the upstream signal.\",\n      \"evidence\": \"Immunofluorescence of XRCC1 foci in PARP-1 KO MEFs and BRCT1 mutants after H₂O₂\",\n      \"pmids\": [\"14500814\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PARP-2 redundancy not tested\", \"Whether PAR binding is direct via BRCT1 or indirect not resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Systematic biochemical dissection showed the primary defect in XRCC1-deficient cells is impaired nick ligation rather than base excision or gap filling, pinpointing the rate-limiting step controlled by XRCC1.\",\n      \"evidence\": \"Whole-cell extract BER/SSBR assays across multiple substrates in EM9 cells\",\n      \"pmids\": [\"16245950\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this reflects ligase III stabilization or direct ligation stimulation not distinguished\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of CK2 as the kinase that phosphorylates XRCC1 to stabilize the XRCC1–ligase IIIα complex provided the first post-translational regulatory mechanism controlling XRCC1 protein levels and repair capacity.\",\n      \"evidence\": \"Kinase activity screen in cell extracts, CK2 siRNA, phosphosite mutants, co-immunoprecipitation, comet assay\",\n      \"pmids\": [\"20471329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other kinases or phosphatases that modulate XRCC1 not explored\", \"CK2 regulation in response to damage not characterized\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Direct PAR binding by the XRCC1 BRCT1 phosphate-binding pocket was shown to be necessary for PARP-1 interaction, damage recruitment, and repair acceleration, resolving that XRCC1 senses PAR through its BRCT1 domain rather than through protein–protein contact with PARP-1.\",\n      \"evidence\": \"PAR-binding assays with BRCT1 mutants, PARP-1 co-IP, live-cell damage recruitment, BER/SSBR and clonogenic assays\",\n      \"pmids\": [\"26130715\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural details of BRCT1–PAR interaction at atomic resolution not available\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Human XRCC1 biallelic loss-of-function mutations were linked to cerebellar ataxia and neurodegeneration, and genetic rescue by PARP1 deletion in mice identified PARP1 hyperactivation as the pathogenic driver, transforming understanding from a DNA repair deficiency model to one of toxic PARP1 signaling.\",\n      \"evidence\": \"Patient fibroblast SSBR/PAR assays, Xrcc1/Parp1 double-KO mouse with cerebellar neuron counts and ADP-ribosylation quantification\",\n      \"pmids\": [\"28002403\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors of toxic PARylation in neurons not fully delineated\", \"Whether other tissues are similarly affected by PARP hyperactivation unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Establishing that PARP1 and PARP2 are redundant for XRCC1 recruitment explained why single PARP KOs show mild repair phenotypes, requiring loss of both PARPs to ablate XRCC1 chromatin binding.\",\n      \"evidence\": \"Isogenic PARP1/PARP2 single and double KO human cells with chromatin fractionation after H₂O₂\",\n      \"pmids\": [\"27965414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PARP3 contributes under specific damage contexts not fully excluded\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovery that SIRT1-mediated deacetylation protects XRCC1 from β-TrCP-dependent ubiquitination and degradation identified a second post-translational axis (acetylation/ubiquitination) controlling XRCC1 stability, complementing the CK2 phosphorylation mechanism.\",\n      \"evidence\": \"Site-directed mutagenesis of K260/K298/K431, ubiquitination assay, cycloheximide chase, SIRT1 knockdown\",\n      \"pmids\": [\"31043584\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acetyltransferase that targets these lysines not identified\", \"Interplay between CK2 phosphorylation and SIRT1 deacetylation not studied\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The 'anti-trapper' model was established: XRCC1 prevents toxic PARP1 trapping on BER intermediates, and in its absence PARP1 hyperactivation triggers USP3-mediated histone de-ubiquitination that suppresses transcription — unifying the repair scaffold and transcription-recovery phenotypes under one mechanism.\",\n      \"evidence\": \"PARP1 chromatin trapping assay, BER intermediate accumulation, PARP1/XRCC1 double KO rescue, EU-incorporation transcription recovery, USP3 KO/inhibition in patient fibroblasts and mouse neurons\",\n      \"pmids\": [\"34102106\", \"34811483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PARP1 trapping contributes to alt-EJ phenotypes not tested\", \"Structural basis for how XRCC1 displaces trapped PARP1 unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic-resolution structural basis for how XRCC1 displaces trapped PARP1 from BER intermediates, the complete spectrum of post-translational modifications governing XRCC1 regulation in vivo, and the extent to which XRCC1's role in alternative end-joining at replication forks contributes to genome instability in BRCA-deficient cancers.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of full-length XRCC1 in complex with trapped PARP1\", \"Complete PTM regulatory network not mapped\", \"Alt-EJ role at replication forks studied in single lab only\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 5, 6, 11, 23]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 8, 9, 14, 16]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [8, 14, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 2, 5, 6, 11, 14, 15, 23, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"complexes\": [\n      \"XRCC1–DNA ligase IIIα complex\",\n      \"XRCC1–pol β–ligase III–PARP1 BER complex\",\n      \"XRCC1–PNK–pol β–ligase III SSBR complex\"\n    ],\n    \"partners\": [\n      \"LIG3\",\n      \"POLB\",\n      \"PARP1\",\n      \"PARP2\",\n      \"PNKP\",\n      \"APEX1\",\n      \"PCNA\",\n      \"CSNK2A1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}